Showing results (511-520 of 586) with videos related to

Sort By:
Pageof 59
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2018
Precision Oncology Decision Support: Current Approaches and Strategies for the FutureKatherine C Kurnit, Ecaterina E Ileana Dumbrava, Beate Litzenburger, et al.
Cancer Cell|March 14, 2018
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination DeficiencyChaoyang Sun, Jun Yin, Yong Fang, et al.
Nature Medicine|January 13, 2026
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trialTimothy A Yap, Randy F Sweis, Ulka Vaishampayan, et al.
Acta Histochemica|February 22, 2020
Comparative histological studies on properties of polysaccharides secreted by vomeronasal glands of eight Laurasiatheria speciesDaisuke Kondoh, Jumpei Tomiyasu, Raito Itakura, et al.
Clinical Pharmacology and Therapeutics|August 21, 2025
Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor TuvusertibJatinder Kaur Mukker, Paul Matthias Diderichsen, Farina Hellmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2011
Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studiesTimothy A Yap, David Olmos, Andre T Brunetto, et al.
NPJ Precision Oncology|April 18, 2023
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignanciesOmar Alhalabi, Roman Groisberg, Ralph Zinner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2023
SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth SuppressionChuandong Geng, Man-Chao Zhang, Ganiraju C Manyam, et al.
JAMA Oncology|November 17, 2022
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled TrialTimothy A Yap, Aditya Bardia, Michael Dvorkin, et al.
NPJ Breast Cancer|December 3, 2025
CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screenNealia C House, Maxine M Chen, Sima Khazaei, et al.
Pageof 59